

**Principles and Framework to Guide the Development of Protocols and Standard Operating Procedures
for Face and Hand Transplants Open Session**

January 31, 2024

Speakers' Biosketches

Colonel (ret.) Michael Davis, MD, FACS, is the Chief Strategic Officer of the Metis Foundation. Dr. Davis recently retired after 26 years of military service and accumulated an extensive, rare knowledge base involving the clinical, scientific, operational, and governmental programmatic domains. He has garnered numerous military and medical publications and awards, serves as a reviewer for professional journals and is a Fellow of the American College of Surgeons. Michael previously served in escalating Department of Defense programmatic roles as Deputy Commander, US Army Institute of Surgical Research and culminating over the past three years as Director, US Combat Casualty Care Research Program- the Department's largest medical R&D program. Previously, while deployed to Afghanistan in support of Operation Enduring Freedom from 2009-2010, Dr. Davis served as Chief of Reconstructive Surgery. Additionally, he founded and directed the RESTOR (Restorative Endeavor for Servicemembers through Optimization of Reconstruction) Research Program in San Antonio for advanced reconstructive surgery research for injured warfighters. Dr. Davis began his career with a residency in General Surgery/Trauma at the University of Texas Health Science Center, San Antonio, TX. During his General Surgery residency, he completed a research fellowship in vascular surgery at Wilford Hall Medical Center, Lackland AFB, TX. Dr. Davis completed an additional residency in Plastic and Reconstructive Surgery at the University of Alabama at Birmingham. Dr. Davis received his MD from the Uniformed Services University of the Health Sciences.

Vijay S. Gorantla, MD, PhD, FRCS, is Professor (with tenure) of Surgery, Ophthalmology and Bioengineering at the Wake Forest School of Medicine. Dr. Gorantla received his medical degree from the University of Health Sciences and pursued clinical training at King George Hospital. He completed postgraduate surgical training in Manchester, United Kingdom, followed by post-doctoral fellowships in microsurgery, plastic and reconstructive surgery and hand surgery at the University of Louisville and the Christine M. Kleinert Institute for Hand and Microsurgery, Kentucky. Dr. Gorantla played a key role in the Nation's first hand transplant program at the University of Louisville before joining the University of Pittsburgh Medical Center, where his efforts were fundamental to the institutional approval, federal funding, and establishment of the Nation's second upper extremity transplant program. He served as Medical Director of the UPMC Hand Transplant program for 10 years and oversaw the management of 8 hand transplants including the Nation's first male and female bilateral hand transplants. He joined the Wake Forest School of Medicine in 2017 as the Director of the Vascularized Composite Allotransplantation Program. He also serves as the Chief Scientist for the RESTOR Program (59th Medical Wing, US Air Force), Office of the Deputy Commander of the United States Army Institute for Surgical Research, at the Brooke Army Medical Center. Dr. Gorantla is currently the President of the International Society of Vascularized Composite Allotransplantation which is the largest, global alliance for reconstructive transplantation. Dr. Gorantla is also founding member and board member of the American Society for Reconstructive Transplantation. He serves as council member on the OPTN/UNOS

VCA Committee and is the co-chair of the Transplant Regenerative Medicine Community of Practice at the American Society for Transplantation. Dr. Gorantla has also served on the Leadership and Innovation Council at the Organ Donation and Transplantation Alliance. Dr. Gorantla's academic interests relate to translational and clinical research in restorative surgery, tissue engineering and regenerative medicine to address the critical needs of service men and women with traumatic injuries. As a surgeon-scientist, over the last decade, he has been funded in convergent technologies that involve disruptive or transformative strategies in the restoration or rehabilitation of disabilities secondary to complex limb loss, traumatic brain injury or vision loss. Dr. Gorantla has a Masters in Medical Management from Carnegie Mellon University focused on healthcare innovation in areas of e-health, telemedicine, precision medicine, pharmacogenomics, population health, and predictive analytics to improve health related quality of life outcomes. Dr. Gorantla is a member of the Transplantation Society, American Society of Reconstructive Microsurgery, World Society for Reconstructive Microsurgery, the American Society of Transplantation, the Plastic Surgery Research Council, and the Kleinert Society.

Patricia Henry, PhD, currently supports CDMRP as a civilian Program Manager for the Armed Forces Institute of Regenerative Medicine (AFIRM), Bone Marrow Failure Research Program, and the Reconstructive Transplant Research Program (RTRP). In addition, she provides program management support for the regenerative medicine and musculoskeletal injury portfolios, which are aligned to the Combat Casualty Care Research Program (CCCRP) and Military Operational Medicine Research Program (MOMRP), respectively. As such, she provides program management duties for funding opportunities released under the Defense Medical Research and Development Program (DMRDP) and the Broad Agency Announcement. As Program Manager, Dr. Henry is responsible for administering the program life cycle to include annual review of the program vision and mission, strategic planning of an investment strategy, development and release of research funding opportunities, oversight of the two-tier review of research proposals, and overall program management and evaluation. Dr. Henry currently serves on several CDMRP working groups, including the Small Business Innovation Research Working Group and Mechanism Mapping Working Group. She also serves on the Musculoskeletal Injury Integrated Product Team. She previously served as Chair for the Regenerative Medicine Working Group, which was an inter-agency committee composed of members from CDMRP, Clinical and Rehabilitative Medicine Research Program, United States Army Medical Materiel Development Activity, and the Office of Regulatory Affairs. Prior to taking on Program Management duties in May 2016 Dr. Henry served as a Civilian Science Officer for the Spinal Cord Injury Research Program. Dr. Henry received a Ph.D. in molecular and cell biology from the University of Maryland and completed a postdoctoral fellowship with the National Cancer Institute's HIV Drug Resistance Program.

Bohdan Pomahac, MD, is Division Chief of Plastic & Reconstructive Surgery. Dr. Pomahac joined the Yale Surgery and Smilow Cancer Hospital community from Brigham and Women's Hospital and Harvard Medical School, where he was the Roberta and Stephen R. Weiner Distinguished Chair in Surgery and Director of Vascular Composite Allograft Transplantation program. A pioneer in his field, Dr. Pomahac's team performed the first three full-face transplant procedures in the United States, and co-led the team that performed the first successful bilateral upper extremity transplantation in the Northeast. Dr. Pomahac made Brigham and Women's Hospital the world leader in vascularized composite transplantation completing 10 face and 4 bilateral hand transplants. Dr. Pomahac's expertise adds to a growing portfolio of destination programs in the Division of Plastic & Reconstructive Surgery at Yale,

which has grown into a multidisciplinary enterprise—with novel programs across Connecticut, including wound healing, craniofacial surgery, melanoma treatment, targeted muscle reinnervation, breast reconstruction, and cutting-edge research in machine learning and 3D printing.

Judi A. Sgambato, PhD, currently serves as a Science Officer (SO) for the Congressionally Directed Medical Research Programs (CDMRP), U.S. Army Medical Research and Development Command (USAMRDC) supporting the Reconstructive Transplant Research Program (RTRP) and the Rare Cancers Research Program (RCRP). Her previous roles include: Scientist at the National Institutes of Health-National Center for Advancing Translational Sciences where she worked to develop and optimize protocols for the differentiation of human pluripotent stem cells, particularly towards pancreatic insulin producing cells; and Research Scientist at Battelle Memorial Institute where she contributed to and lead various Government and commercial research projects. This included the development of a molecular biothreat detection assay in support of the Joint Program Executive Office for Chemical and Biological Defense's Global Biosurveillance Technology Initiative; the development of novel influenza surveillance assays for the Health and Human Services Centers for Disease Control; and the development of a stem cell-based cardiomyocyte toxicity assay for the in vitro evaluation of cardiac safety during drug screening. Dr. Sgambato holds a Ph.D. degree in Molecular Medicine from the University of Maryland Baltimore in 2014 and a Bachelors of Science in Biology from the University of Maine (2008).